Iteos Therapeutics Inc ITOS.OQ ITOS.O is expected to show a fall in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Iteos Therapeutics Inc is for a loss of $1.01 per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Iteos Therapeutics Inc is $10.27, about 1.8% above its last closing price of $10.09
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.86 | -0.95 | -0.80 | Beat | 15.9 |
Dec. 31 2025 | -1.05 | -1.06 | -1.03 | Beat | 3.2 |
Sep. 30 2024 | -1.15 | -0.89 | -1.05 | Missed | -18.1 |
Jun. 30 2024 | -1.04 | -1.04 | -0.18 | Beat | 82.7 |
Mar. 31 2024 | -0.97 | -1.26 | -1.07 | Beat | 14.8 |
Dec. 31 2023 | -0.93 | -1.03 | -0.85 | Beat | 17.7 |
Sep. 30 2023 | -1.14 | -1.20 | -0.90 | Beat | 25.2 |
Jun. 30 2023 | -0.98 | -1.03 | -0.96 | Beat | 6.8 |
This summary was machine generated August 4 at 12:56 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)